Joon-Hyop Lee1,2, Ra-Yeong Song3, Jin Wook Yi3, Hyeong Won Yu3, Hyungju Kwon3, Su-Jin Kim3,4, Young Jun Chai5, June Young Choi1, Jae Hoon Moon6, Kyu Eun Lee7,8, Young Joo Park4,9, Sue K Park4,10. 1. Department of Surgery, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea. 2. Thyroid and Endocrine Surgery Section, Department of Surgery, Gachon University Gil Medical Center, Incheon, Republic of Korea. 3. Department of Surgery, Seoul National University Hospital and College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, Republic of Korea. 4. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. 5. Department of Surgery, Seoul National University Hospital Boramae Medical Center, Seoul, Republic of Korea. 6. Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea. 7. Department of Surgery, Seoul National University Hospital and College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, Republic of Korea. kyueunlee@snu.ac.kr. 8. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. kyueunlee@snu.ac.kr. 9. Department of Internal Medicine, Seoul National University Hospital and College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, Republic of Korea. 10. Department of Preventive Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, Republic of Korea.
Abstract
BACKGROUND: The association between iodine levels and the risk of papillary thyroid cancer (PTC) has been suggested, but not definitively established. This study is to compare the iodine status of a group of patients with PTC (with and without BRAF V600E) with that of a healthy population cohort. METHODS: A cohort of patients scheduled for thyroidectomy was enrolled, along with a community-based health-screening cohort with no known history of thyroid disease. Median urinary iodine (UI) levels, creatinine-adjusted median UI levels, and food frequency questionnaire (FFQ) scores (mean ± SD) were compared. In a subgroup analysis, these values were compared between BRAF V600E-positive and BRAF V600E-negative patients in the PTC group. RESULTS: The PTC group consisted of 210 patients, and the control group consisted of 90 healthy individuals. Among the 191 PTC patients whose BRAF V600E mutational status was reported, 169 (88.5%) were revealed positive for the mutation. The median UI levels were significantly higher in the PTC group (786.0 μg/l) than the control group (112.0 μg/l; p < 0.001), as was the case with creatinine-adjusted median UI levels (884.6 μg/g creatinine versus 182.0 μg/g creatinine; p < 0.001) and FFQ scores (66.2 ± 17.5, range 13-114 versus 54.6 ± 21.5, range 16-134; p < 0.001). No significant differences were seen in the subgroup analysis between BRAF V600E-positive and BRAF V600E-negative patients. CONCLUSIONS: Our results indicate that iodine status differs significantly between patients with PTC and healthy controls, suggesting that iodine may be involved in the occurrence of PTC, although the association between iodine levels and BRAF mutational status did not reach statistical significance.
BACKGROUND: The association between iodine levels and the risk of papillary thyroid cancer (PTC) has been suggested, but not definitively established. This study is to compare the iodine status of a group of patients with PTC (with and without BRAFV600E) with that of a healthy population cohort. METHODS: A cohort of patients scheduled for thyroidectomy was enrolled, along with a community-based health-screening cohort with no known history of thyroid disease. Median urinary iodine (UI) levels, creatinine-adjusted median UI levels, and food frequency questionnaire (FFQ) scores (mean ± SD) were compared. In a subgroup analysis, these values were compared between BRAFV600E-positive and BRAFV600E-negative patients in the PTC group. RESULTS: The PTC group consisted of 210 patients, and the control group consisted of 90 healthy individuals. Among the 191 PTCpatients whose BRAFV600E mutational status was reported, 169 (88.5%) were revealed positive for the mutation. The median UI levels were significantly higher in the PTC group (786.0 μg/l) than the control group (112.0 μg/l; p < 0.001), as was the case with creatinine-adjusted median UI levels (884.6 μg/g creatinine versus 182.0 μg/g creatinine; p < 0.001) and FFQ scores (66.2 ± 17.5, range 13-114 versus 54.6 ± 21.5, range 16-134; p < 0.001). No significant differences were seen in the subgroup analysis between BRAFV600E-positive and BRAFV600E-negative patients. CONCLUSIONS: Our results indicate that iodine status differs significantly between patients with PTC and healthy controls, suggesting that iodine may be involved in the occurrence of PTC, although the association between iodine levels and BRAF mutational status did not reach statistical significance.
Authors: C Bosetti; L Kolonel; E Negri; E Ron; S Franceschi; L Dal Maso; M R Galanti; S D Mark; S Preston-Martin; A McTiernan; C Land; F Jin; G Wingren; A Hallquist; E Glattre; E Lund; F Levi; D Linos; C La Vecchia Journal: Cancer Causes Control Date: 2001-05 Impact factor: 2.506
Authors: Yun Mi Choi; Tae Yong Kim; Eun Kyung Jang; Hyemi Kwon; Min Ji Jeon; Won Gu Kim; Young Kee Shong; Won Bae Kim Journal: Endocrinol Metab (Seoul) Date: 2014-12-29
Authors: Joon-Hyop Lee; Sora Youn; Sohee Jung; Kwangsoo Kim; Young Jun Chai; Yoo Seung Chung; Won Seo Park; Kyu Eun Lee; Ka Hee Yi Journal: Sci Rep Date: 2020-10-20 Impact factor: 4.379